Clinical trial
A Phase 2a, Dose Escalation Study to Evaluate the Effect of RT234 on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
NCT05343637 is registered in ClinicalTrials.gov with Respira Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Dose Escalation Study to Evaluate the Effect of RT234 on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
- Lead sponsor
- Respira Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 30, 2019
- Completion date
- January 17, 2020
- Enrollment
- 14 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.